Accession Number:

ADA561074

Title:

Biocompatible, Biodegradable, and Enzymatic-Cleavable MRI Contrast Agents for Early Detection of Bone Metastatic Breast Cancer

Descriptive Note:

Annual rept. 1 Apr 2011- 31 Mar 2012

Corporate Author:

UTAH UNIV SALT LAKE CITY

Personal Author(s):

• Wang, Xuli

Report Date:

2012-04-01

Pagination or Media Count:

9.0

Abstract:

This project proposes to design and test a novel peptide-based MRI contrast agent for early detection of bone metastasis from breast cancer. The proposed imaging agent is consist of bone targeting moiety of Asp8 and MRI imaging moiety of DOTAGd with a cathepsin K cleavable peptide spacer. A solid phase peptide synthesis SPPS strategy was used to synthesize peptides. Coupling of the peptide onto DOTA followed by Gd complexation was performed to achieve the proposed imaging agent. Non-targeting and CTSK-insensitive controls were similarly prepared. The obtained contrast agents were characterized in terms of bone specificity, enzymatic degradability and biocompatibility. Preliminary testing of contrast enhanced MR imaging at different time points is ongoing in mice with bone metastasis from breast cancer.

Descriptors:

• *BREAST CANCER
• BONES
• MAGNETIC RESONANCE IMAGING
• METASTASIS
• PEPTIDES

Subject Categories:

• Anatomy and Physiology
• Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE